Bleichroeder Entities and Andrew Gundlach Disclose 9.69% Stake in DTIL

Rhea-AI Filing Summary

Schedule 13G summary: Bleichroeder LP, Bleichroeder Holdings LLC and Andrew Gundlach report beneficial ownership of 1,075,000 common shares of Precision BioSciences, representing 9.69% of the outstanding common stock. The filing shows the reporting persons hold sole voting and sole dispositive power over these shares and report no shared voting or dispositive power. Bleichroeder LP is identified as an investment adviser and is deemed to beneficially own the shares as adviser to various clients, while those clients retain the right to dividends and sale proceeds. The filing is submitted on Schedule 13G with exhibits for an agreement among reporting persons and subsidiary information.

Positive

• Material minority stake: Beneficial ownership of 1,075,000 shares representing 9.69% of common stock is a notable, reportable position.
• Passive disclosure: Filing under Schedule 13G and a certification that holdings are held in the ordinary course and not to influence control indicates the reporting persons characterize the position as non‑activist.

Negative

• None.

Insights

Financial Analyst

TL;DR Schedule 13G discloses a passive 9.69% stake (1,075,000 shares); material size but reported as non‑control.

Bleichroeder entities and Andrew Gundlach report sole voting and dispositive power over 1,075,000 Precision BioSciences common shares, equal to 9.69% of the class. The Schedule 13G classification and the certification state the position is held in the ordinary course of business and not to influence control, which signals a passive, disclosure-driven holding rather than an activist intent. Materiality arises from the near‑double digit stake, which may be meaningful to liquidity and shareholder base concentration, but the filing itself does not assert strategic or control objectives.

Corporate Governance Expert

TL;DR Significant minority ownership disclosed, but filing asserts no purpose of changing or influencing issuer control.

The filing names Bleichroeder LP (an investment adviser), Bleichroeder Holdings LLC and Andrew Gundlach as reporting persons and records sole voting and dispositive power for the full 1,075,000 shares. Item disclosure clarifies Bleichroeder LP is deemed beneficial owner as adviser to various clients while those clients retain economic rights. The use of Schedule 13G and the signed certification emphasize a passive ownership posture; governance impact depends on whether the stake remains passive or evolves in future disclosures.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

PRECISION BIOSCIENCES INC

(Name of Issuer)

Common Shares

(Title of Class of Securities)

74019P207

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 74019P207

1

Names of Reporting Persons

Bleichroeder LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,075,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,075,000.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,075,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.69 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP No. 74019P207

1

Names of Reporting Persons

Bleichroeder Holdings LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,075,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,075,000.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,075,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.69 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP No. 74019P207

1

Names of Reporting Persons

Andrew Gundlach

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,075,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,075,000.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,075,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.69 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: PRECISION BIOSCIENCES INC
(b)	Address of issuer's principal executive offices: 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM, NC 27701
Item 2.
(a)	Name of person filing: Bleichroeder Holdings LLC Bleichroeder LP Andrew Gundlach
(b)	Address or principal business office or, if none, residence: 1345 Avenue of the Americas, 47th Floor New York, NY 10105
(c)	Citizenship: Bleichroeder Holdings LLC and Bleichroeder LP: Delaware, USA Andrew Gundlach: United States
(d)	Title of class of securities: Common Shares
(e)	CUSIP No.: 74019P207
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See cover page.
(b)	Percent of class: See cover page.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See cover page.
	(ii) Shared power to vote or to direct the vote: See cover page.
	(iii) Sole power to dispose or to direct the disposition of: See cover page.
	(iv) Shared power to dispose or to direct the disposition of: See cover page.
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Bleichroeder LP ("Bleichroeder"), an investment adviser registered under Section 203 of the Investment Advisers Act of 1940, is deemed to be the beneficial owner of 1,075,000 shares, or 9.69% of the common stock believed to be outstanding as a result of acting as investment adviser to various clients. Clients of Bleichroeder have the right to receive and the ultimate power to direct the receipt of dividends from, or the proceeds of the sale of, such securities.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. ee Exhibit 99.1
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Bleichroeder LP

Signature:	Andrew Gundlach
Name/Title:	President and CEO
Date:	08/12/2025

Bleichroeder Holdings LLC

Signature:	Andrew Gundlach
Name/Title:	President and CEO
Date:	08/12/2025

Andrew Gundlach

Signature:	Andrew Gundlach
Name/Title:	President and CEO
Date:	08/12/2025

Exhibit Information

Exhibit 1: Agreement of the Reporting Persons Exhibit 2: Subsidiary Information

FAQ

How many Precision BioSciences (DTIL) shares do Bleichroeder and affiliates report owning?

They report beneficial ownership of 1,075,000 shares, representing 9.69% of Precision BioSciences common stock.

Does the Schedule 13G indicate the holders intend to influence control of DTIL?

No. The filing includes a certification stating the securities are held in the ordinary course of business and not for the purpose of changing or influencing control.

Who are the reporting persons on the filing for DTIL?

The reporting persons are Bleichroeder LP, Bleichroeder Holdings LLC and Andrew Gundlach.

What voting and dispositive powers are reported for the DTIL shares?

The reporting persons disclose sole voting power of 1,075,000 shares and sole dispositive power of 1,075,000 shares; shared powers are reported as 0.

Are the shares held on behalf of clients?

Yes. The filing states Bleichroeder LP, an investment adviser, is deemed beneficial owner as adviser to various clients, and those clients retain the right to dividends and sale proceeds.